China

UK major will bag CSPC’s eight preclinical drug candidates in weight management, including most advanced asset SYH2082, a long-acting GLP-1/GIP receptor agonist with once-monthly dosing potential.

Multiple Chinese biotechs are seeking to raise new funds through IPOs on the Hong Kong and Beijing stock exchanges to support international clinical trials for their first-in-class molecules.

Deal Snapshot: The German group is the latest big pharma to partner with one of China's most prolific dealmakers in an agreement that could be worth over $1bn.

The medtech industry has been disrupted by tariffs and China’s volume-based procurement policies. While India is expected to emerge as a key long-term growth market, near-term upside may come from a potential rebound in EU attractiveness following the MDR reform proposals in December 2025.

Scrip senior editor Jessica Merrill, Scrip US managing editor Mandy Jackson and In Vivo senior reporter David Wild discuss trends and topics from interviews and presentations at the J.P. Morgan Healthcare Conference and Biotech Showcase.

Generics Bulletin reviews global regulatory developments across the world.

“We remain fully committed to the integrated growth strategy that has enabled us to deliver significant growth and value creation, over the better part of the past decade,” says CEO Shailesh Jejurikar as firm reports net sales up 1% in latest quarter.

While a record number of China-originated first-in-class drugs were approved domestically in 2025, only one has so far entered clinical development overseas with its originator as the sole sponsor. But more progress is expected this year.

With capital being recycled, tariffs settling and interest rates softening, 2026 could provide more investment and growth opportunities in pharma and medtech, with AI giving a tailwind, say Taylor Wessing’s Ross McNaughton and Sarah Cole.

While the regulatory environment for vaccines sours in the US, Valneva tells Scrip it is mulling an Asia hub and finalizing a strategy - that includes partnerships - for its marketed and pipeline products. Could it consider India or China as a new regional center?

Amphastar is looking to a “strategically important addition to our growing proprietary peptide portfolio,” after striking an exclusive licensing agreement with China-based Nanjing Hanxin Pharmaceutical Technology.

The $172m acquisition will bring in Kylo-11, a Lp(a) inhibitor with potential once-yearly dosing, as well as other ultra long-acting siRNA candidates directed at APOC3, PCSK9 and other undisclosed targets in cardiovascular diseases.